Human gastric cancer is one of the most common malignant tumors with a poor prognosis. Cisplatin (CDDP) is a well‐known first‐line chemotherapeutic drug. Acquired resistance retards the clinical application of CDDP in gastric cancer. In this study, circular RNA circ_0026359 was demonstrated to be overexpressed in gastric cancer tissues/cells compared with normal gastric tissues/cells and was overexpressed in CDDP‐resistant gastric cancer tissues/cells compared with CDDP‐sensitive gastric cancer tissues/cells. High levels of circ_0026359 were associated with low overall survival (OS) and relapse‐free survival (RFS) rates in gastric cancer patients. circ_0026359 was examined to promote CDDP resistance in gastric cancer cells. circ_0026359 directly interacted and negatively regulated miR‐1200. POLD4 was a direct target of miR‐1200. miR‐1200/POLD4 pathway mediated the promoting role of circ_0026359 in CDDP resistance of gastric cancer. circ_0026359 could be used as a potential target for CDDP‐resistant gastric cancer therapy.

The objective of this study was to explore the potential genetic link between Crohn’s disease and breast cancer, with a focus on identifying druggable genes that may have therapeutic relevance. We assessed the causal relationship between these diseases through Mendelian randomization and investigated gene-drug interactions using computational predictions. This study sought to identify common genetic pathways possibly involved in immune responses and cancer progression, providing a foundation for future targeted treatment research. The dataset comprises single nucleotide polymorphisms used as instrumental variables for Crohn’s disease, analyzed to explore their possible impact on breast cancer risk. Gene ontology and pathway enrichment analyses were conducted to identify genes shared between the two conditions, supported by protein–protein interaction networks, colocalization analyses, and deep learning-based predictions of gene-drug interactions. The identified hub genes and predicted gene-drug interactions offer preliminary insights into possible therapeutic targets for breast cancer and immune-related conditions. This dataset may be valuable for researchers studying genetic links between autoimmune diseases and cancer and for those interested in the early identification of potential drug targets.

Background: Despite substantial progress in graft materials and surgical techniques, arterial graft infections continue to pose significant clinical challenges. The optimal graft material remains debated, with prosthetic grafts being associated with elevated reinfection and mortality rates. Given the growing interest in xenogeneic pericardium, this study aimed to systematically evaluate its efficacy and safety in the management of prosthetic graft infections. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. PubMed/MEDLINE and the Cochrane Library were searched up to July 7, 2024. Studies reporting on the use of xenogeneic pericardium for vascular reconstruction in prosthetic graft infections were included. Data on demographics, clinical outcomes, reinfection rates, mortality, graft patency, and complications were extracted. Results: Eight studies involving 222 patients (182 males; mean age 67.7 ± 9.1 years) were included. Microbial analysis of 190 culture-positive cases identified Staphylococcusspecies (20%), fungi (14%), Enterococcus faecalis (12%), Streptococcusspp. (11%), and Escherichia coli (10%) as the most common pathogens. Mean follow-up duration ranged from 9 to 26 months. Cumulative mortality rates were 13% (95% CI: 8%–18%) at 30 days, 32% (95% CI: 25%–39%) at 1 year, and 35% (95% CI: 29%–42%) at 2 years. The reinfection rate was 5% (95% CI: 2%–9%), while graft occlusion and anastomotic pseudoaneurysm rates were both 3% (95% CIs: 0%–6% and 1%–7%, respectively). Conclusion: Xenogeneic pericardium is a viable alternative for vascular reconstruction in graft infection scenarios, associated with acceptable reinfection and complication rates. It offers a promising option, particularly when autologous or allograft materials are unavailable.